...
首页> 外文期刊>European Archives of Psychiatry and Clinical Neuroscience >Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
【24h】

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

机译:神经心理药理学中的治疗性药物监测:它能否兑现其诺言?

获取原文
获取原文并翻译 | 示例

摘要

To produce its characteristic effects, a drug must be present in appropriate concentrations at its sites of action. The latter is not only a function of the dose administered, but also of the extent and rate of drug absorption, distribution, tissue binding, biotransformation, and excretion, which can vary markedly between individual patients due to differences in gender, age, morbidity, smoking or eating habits, differential expression of drug metabolising enzymes or drug transporters or other factors. Therefore drug concentrations in blood resulting after a given dose differ by tenfold or more between individual patients. For psychoactive drugs, animal studies have shown that plasma concentrations of psychotropic drugs correlate well with concentrations in the target organ, the brain. In the brain of patients treated with antipsychotic or antidepressant drugs clear-cut relationships were found between plasma concentrations of the drug and occupancy of dopamine receptors or serotonin uptake sites by positron emission tomography (PET). Monitoring concentrations of psychoactive drugs in plasma of patients, so called therapeutic drug monitoring (TDM), is therefore useful to adjust dosages for optimal “receptor” blockade. TDM is well established for mood stabilizers and anticonvulsant drugs. For other neuropsychiatric drugs, however, “routine” TDM is rare. Optimal target concentrations are unclear for many drugs, and the number of laboratories that use reliable methods to measure the low concentrations of the drugs within a single day is quite limited. Moreover, the use of TDM in pratice is far from optimal. The TDM group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP see http://www.agnp.de/) has published literature-based guidelines for optimal use of TDM in psychiatry. TDM can be most informative to solve problems underlying the treatment of an individual patient. It can be clarified if suggested non-compliance or insufficient response in spite of recommended doses is due to rapid metabolism of the drug. Moreover, many drug interactions have been detected by using TDM. In conclusion, TDM is a reliable tool to optimise psychopharmacotherapy. When used adequately it is helpful for many psychiatric patients and in many situations.
机译:为了产生其特有的作用,药物必须以适当的浓度存在于其作用部位。后者不仅取决于给药剂量,还取决于药物吸收,分布,组织结合,生物转化和排泄的程度和速率,由于性别,年龄,发病率,吸烟或饮食习惯,药物代谢酶或药物转运蛋白的差异表达或其他因素。因此,在给定剂量后,各个患者之间血液中的药物浓度相差十倍甚至更多倍。对于精神活性药物,动物研究表明,精神药物的血浆浓度与目标器官(大脑)中的浓度密切相关。在接受抗精神病药或抗抑郁药治疗的患者的大脑中,发现该药物的血浆浓度与通过正电子发射断层扫描(PET)测得的多巴胺受体或5-羟色胺摄取部位之间存在明确的关系。因此,监测患者血浆中精神活性药物的浓度(所谓的治疗药物监测(TDM))可用于调整剂量,以实现最佳的“受体”阻滞。 TDM在情绪稳定剂和抗惊厥药物方面已广为接受。但是,对于其他神经精神科药物,“常规” TDM很少见。许多药物的最佳靶标浓度尚不清楚,并且使用可靠方法测量一天之内低浓度药物的实验室数量非常有限。而且,在实践中使用TDM远非最佳。神经精神药物和精神病学的Arbeitsgemeinschaft和PharmakoPsychiatrie的TDM小组(AGNP,请参见http://www.agnp.de/)已经出版了有关在精神病学中最佳使用TDM的基于文献的指南。 TDM对于解决单个患者的治疗潜在的问题可能是最有用的。可以澄清,尽管建议的剂量是建议的不依从或反应不足,是由于药物的新陈代谢引起的。而且,已经通过使用TDM检测到许多药物相互作用。总之,TDM是优化心理药物疗法的可靠工具。如果使用得当,它对许多精神病患者和许多情况都有帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号